Endo International plc is a global specialty pharmaceutical company focused on improving the lives of patients while creating value. Endo develops, manufactures, markets and distributes quality branded and generic pharmaceutical products as well as over-the-counter medications through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs, SOMAR and Litha. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Since that time, the company has expanded to include the following business segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals. Endo’s strategy is to maximize value for our key stakeholders by employing an efficient operating model with focused and disciplined execution that allows us to pursue growth opportunities both organically and through selective acquisitions. Additionally, we are leveraging a research and development model that focuses on lower risk, near-term projects. Our goal is to consistently create value for our shareholders while serving our patients and customers. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 6,000 people worldwide.
Show more
Type
Public
HQ
Ballsbridge, IE
Founded
1997
Website
endo.com
Endo International was founded in 1997 and is headquartered in Ballsbridge, IE
Report incorrect company information

Endo International Office Locations

Endo International has offices in Malvern, Ballsbridge, Cranbury Township, Horsham and in 16 other locations
Ballsbridge, IE (HQ)
4 Pembroke Gardens
Midrand, ZA
106 16th Rd
Watford, GB
Clarendon Rd
Charlotte, US
3241 Woodpark Blvd
Charlotte, US
3700 Woodpark Blvd
Chestnut Ridge, US
6 Ram Ridge Rd
Show all (25)
Report incorrect company information

Endo International Financials and Metrics

Endo International Financials

Endo International's revenue was reported to be $3.47 b in FY, 2017
USD

Revenue (FY, 2017)

3.5 b

Gross profit (FY, 2017)

1.2 b

Gross profit margin (FY, 2017), %

35.8%

EBIT (FY, 2017)

(960.1 m)

Market capitalization (31-Oct-2017)

1.4 b

Closing share price (31-Oct-2017)

6

Cash (31-Dec-2017)

986.6 m

EV

467.6 m
Endo International's current market capitalization is $1.4 b.
USDFY, 2017

Revenue

3.5 b

Cost of goods sold

2.2 b

Gross profit

1.2 b

Gross profit Margin, %

36%
USDFY, 2017

Cash

986.6 m

Inventories

391.4 m

Current Assets

2.3 b

PP&E

524 m
USDFY, 2017

Depreciation and Amortization

983.8 m

Inventories

147.2 m

Accounts Payable

(69.6 m)

Cash From Operating Activities

554 m
USDY, 2017

EV/EBIT

-0.5 x

EV/CFO

0.8 x

Financial Leverage

24 x
Show all financial metrics
Report incorrect company information